Assessment of Platelet Indices in Patients with Neurodegenerative Diseases: Mean Platelet Volume Was Increased in Patients with Parkinson’s Disease

Koçer, Abdülkadir; Yaman, Aslı; Niftaliyev, Elvin; Dürüyen, Hümeyra; Eryılmaz, Mehmet; Koçer, Emel

doi:10.1155/2013/986254

Cited by 49 publications

(39 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Since platelets present neuron-like metabolic pathways, previous studies have shown that in 15 AD, APP acts as a platelet-membrane receptor contributing mostly to soluble β-amyloid after platelet activation (Bram et al, 2018). Mitochondrial dysfunction, higher content in phosphorylated TDP43, and morphological and structural platelet changes in AD and PD have also been reported (Koçer et al, 2013;Kucheryavykh et al, 2017). Whether miRNA deregulation in platelets promotes neurodegeneration or merely reflects its effects remains to be elucidated.…”

Section: Discussionmentioning

confidence: 72%

Platelet miRNA bio-signature discriminates between dementia with Lewy bodies and Alzheimer disease

Gámez-Valero

Campdelacreu

Vilas

et al. 2020

Preprint

View full text Add to dashboard Cite

_ 3 The paper explained Problem: Dementia with Lewy bodies (DLB) presents pathological and clinical overlap with both Alzheimer's (AD) and Parkinson's disease (PD), which impairs its correct diagnosis. Although numerous papers report peripheral biomarkers for AD, wellestablished biomarkers for DLB distinguishing it from AD are still missing. Platelet miRNA transcriptome was analyzed in several works, but their putative role as disease biomarkers for neurological disorders has not been assessed. It would be of paramount importance to establish a blood-based bio-signature as a minimally invasive mean for DLB diagnosis, improving differentiation of DLB patients from controls and AD. Results:Our study revealed that platelet miRNAs might be promising biomarkers for the correct diagnosis of DLB stratifying patients in comparison with overlapping disorders, especially AD, and may help to highlight possible disease-related processes.In this cross-sectional study, which includes 162 individuals (DLB, AD, PD and healthy controls), platelet-associated miRNA content was disease group-specific. Three different miRNA sets together with their predicted targeted pathways were defined. Impact:This study suggests that platelet miRNA may serve as DLB biomarker allowing the correct diagnosis and stratification in an easily-applied manner in clinical settings, and may help to highlight possible disease-related processes. 4 ABSTRACT Dementia with Lewy bodies (DLB) is one of the most common causes of degenerative dementia after Alzheimer's disease (AD) and presents pathological and clinical overlap with both AD and Parkinson's disease (PD). Consequently, only one in three DLB cases is diagnosed correctly. Platelets, previously related to neurodegeneration, contain microRNAs (miRNAs) whose analysis may provide disease biomarkers. Here, we profiled the whole platelet miRNA transcriptome from DLB patients and healthy controls. Differentially expressed miRNAs were further validated in three consecutive studies from 2017 to 2019 enrolling 162 individuals, including DLB, AD, and PD patients, and healthy controls. Results comprised a 7-miRNA biosignature, showing the highest diagnostic potential for the differentiation between DLB and AD. Additionally, compared to controls, two miRNAs were down-regulated in DLB, four miRNAs were up-regulated in AD, and two miRNAs were down-regulated in PD. Predictive target analysis identified three disease-specific clusters of pathways as a result of platelet-miRNA deregulation. Our cross-sectional study assesses the identification of a novel, highly specific and sensitive platelet-associated miRNA-based bio-signature, which distinguishes DLB from AD.

show abstract

Section: Discussionmentioning

confidence: 72%

Platelet miRNA bio-signature discriminates between dementia with Lewy bodies and Alzheimer disease

Gámez-Valero

Campdelacreu

Vilas

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…An increase in MPV is associated with other platelet activation markers such as thromboxane and β-thromboglobulin ( 13 ). The relationship with MPV and the prognosis of bloodstream infection as inflammatory markers in active pulmonary tuberculosis and Parkinson’s disease has been shown in the literature ( 21 - 23 ). MPV increase is also seen in varicocele patients, as reported in two studies ( 24 , 25 ).…”

Section: Discussionmentioning

confidence: 97%

Association Between Complete Blood Count Parameters and Urinary Stone Disease

Demiray¹,

Çevik²,

Cuce³

2016

Iran Red Crescent Med J

View full text Add to dashboard Cite

BackgroundComplete blood count (CBC) parameters may associated with multiple diseases. Urinary stone disease is common public problem. Predictive value of CBC parameters may be associated with urinary stone diseaseObjectivesTo analyze the association between complete blood count (CBC) parameters and urinary stone disease.Patients and MethodsThis study was a retrospective observational study of 3,099 patients who were admitted to the urology outpatient clinic or diagnosed with urinary stone disease in the emergency services department. There were 353 patients included in the study that had ultrasonography (USG) and/or non-contrast computerized tomography (NCCT) and a CBC. Patients who had non-urinary system inflammatory disease in USG or NCCT, had fever, non-urinary system infection, anemia or diagnosed hematologic malignancy were excluded (n = 27). Patients were divided into two groups: a stone group (n = 74) and a control group (n = 252). Data of patients were retrieved from the hospital database and statistical analysis was performed.ResultsAn increase in RDW, MPV, PDW, WBC, granulocyte percentage and a decrease in lymphocyte percentage is statistically associated with urinary stone disease (P < 0,001, P < 0.001, P = 0.006, P < 0.001, P = 0.003, P = 0.034, respectively). Microscopic hematuria is associated with urinary stone disease and the odds ratio for urinary stone prediction is 67.7 (P < 0.001). In addition, none of the CBC parameters were associated with stone burden.ConclusionsWhen evaluating flank pain in patients, it is important to remember that CBC parameters may support urinary stone disease, and considering CBC results may be useful in the diagnosis of urinary stone disease.

show abstract

“…47 Interestingly, it has been reported that AD patients have similar platelet counts as age-matched controls, but their platelets are in a more activated state. 48,49 Whether APP/ sAPPs are responsible for the phenotype in our patient cohort is unknown.…”

Section: Org Frommentioning

confidence: 99%

Abnormal clotting of the intrinsic/contact pathway in Alzheimer disease patients is related to cognitive ability

et al. 2018

View full text Add to dashboard Cite

Key Points• Clot initiation and strength are altered in AD patient plasma and transgenic AD mouse model.• Clotting abnormalities are correlated with the cognitive state of AD patients.Alzheimer disease (AD) is a neurodegenerative disorder characterized by extracellular b-amyloid (Ab) deposition. Although peripheral inflammation and cerebrovascular pathology are reported in AD, there is a lack of plasma biomarkers in this field. Because the contact system is triggered in patient plasma, we hypothesized that the hemostasis profile could be a novel biomarker in AD. Here, we assessed the clotting profile in plasma from AD patients and age-matched controls. Utilizing clinically relevant assays, thromboelastography and activated partial thromboplastin time, we found impaired clot initiation and formation rate in AD patient plasma. These coagulation end points correlated with cerebrospinal fluid neurofilament-light levels and cognition and were more profound in younger AD patients. Ex vivo intrinsic clotting of plasma from AD mice expressing human amyloid precursor protein (APP) was also delayed in an age-dependent manner, suggesting that this phenotype is related to APP, the parent protein of Ab. Further analysis of coagulation factors in human plasma indicated that endogenous inhibitor(s) of factors XII and XI in AD plasma contribute to this delayed clotting. Together, these data suggest that delayed clotting in young AD patients is a novel biomarker and that therapies aimed to correct this phenotype might be beneficial in this patient population. Follow-up studies in additional AD patient cohorts are warranted to further evaluate these findings.

show abstract

Assessment of Platelet Indices in Patients with Neurodegenerative Diseases: Mean Platelet Volume Was Increased in Patients with Parkinson’s Disease

Cited by 49 publications

References 39 publications

Platelet miRNA bio-signature discriminates between dementia with Lewy bodies and Alzheimer disease

Platelet miRNA bio-signature discriminates between dementia with Lewy bodies and Alzheimer disease

Association Between Complete Blood Count Parameters and Urinary Stone Disease

Abnormal clotting of the intrinsic/contact pathway in Alzheimer disease patients is related to cognitive ability

Contact Info

Product

Resources

About